Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Efficacy and Safety of Initiation of Biphasic Insulin Aspart 30 Treatment in Subjects With Type 2 Diabetes Mellitus Failing OAD Therapy

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

Inclusion Criteria:

• Type 2 diabetes for at least 24 months
• BMI between 18 and 30 kg/m2
• Insulin naive subjects
• OAD treatment with max two OADs alone or combined with other therapy
• HbA1c between 7-12%

Exclusion Criteria:

• Type 1 diabetes
• Receipt of any investigational drug within the last three months prior to this trial
• Current or previous treatment with thiazolidiones within the last 6 months
• OAD treatment with three or more OADs within the last 4 months